Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01046513 · ClinicalTrials.gov registry record

PET Imaging of Nicotinic Acetylcholine Receptors

A clinical trial of Healthy Volunteers and Nicotine Dependence, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
14
Enrollment target
1
Study location

NCT01046513: Completed study of Healthy Volunteers and Nicotine Dependence, sponsored by National Institute on Drug Abuse (NIDA).

NCT01046513 is a study of Healthy Volunteers and Nicotine Dependence that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 14 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01046513, a study of Healthy Volunteers and Nicotine Dependence, has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
14 participants
Enrollment target
1
Study location

Study Summary

Background: \- Central nicotinic acetylcholine receptors (nAChRs) are the primary target for the action of nicotine. In addition to being involved in tobacco dependence, they are also involved in a variety of brain disorders, including Alzheimer's and Parkinson's diseases. Researchers are interested in developing better ways to study the action of nAChRs to improve treatments for smoking cessation and other problems affected by these receptors. These new study methods may involve different radiotracers, which are drugs that can help show brain activity during positron emission tomography (PET) scanning. Objectives: \- To evaluate the feasibility of using a radiotracer, 2-\[18F\]F-A-85380, in PET scanning of the brain. Eligibility: \- Healthy volunteers between 21 and 45 years of age who do not use tobacco. Design: * Participants will be asked to avoid consuming alcohol or using a number of over-the-counter medications, including antihistamines, cough medicines, and nasal decongestants, for 5 days before the study day. Participants provide urine and breath samples at the start of the study to be tested for chemicals that may interfere with the study. * Participants will visit the clinical center the morning of the day before the scanning session to provide blood and urine samples as required. Participants will return and be admitted for an overnight stay later that afternoon or evening. * On the day of the study, participants will receive a single dose of the radiotracer 2-\[18F\]F-A-85380, and will have a series of PET scans over the next 7 hours and provide blood samples during that time. Participants will spend that night at the clinical center and leave on the morning after the end of the study. * Participants will return for follow-up visits 2 weeks and 1 month after the end of the study.

Study Locations (1)

Maryland

  • National Institute on Drug Abuse, Biomedical Research Center (BRC) - Baltimore

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2007-08-31
Est. Completion 2011-09-28

What the finished NCT01046513 record still lists

NCT01046513 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (97% lower).

The record links to 3 conditions, with Healthy Volunteers appearing as the primary indexed condition, and to 0 interventions.

NCT01046513 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT01046513 about?

NCT01046513 is a clinical study titled "PET Imaging of Nicotinic Acetylcholine Receptors". Background: \- Central nicotinic acetylcholine receptors (nAChRs) are the primary target for the action of nicotine. In addition to being involved in tobacco dependence, they are also involved in a variety of brain disorders, including Alzheimer's and Parkinson's diseases. Researchers are intereste...

What is the current status of trial NCT01046513?

This trial is currently completed. The enrollment target is 14 participants. The study started on 2007-08-31. Estimated completion is 2011-09-28.

What conditions does trial NCT01046513 study?

This clinical trial studies the following conditions: Healthy Volunteers, Nicotine Dependence, Pharmacokinetics.

Who is sponsoring clinical trial NCT01046513?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01046513 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01046513's enrollment target sits among peer trials

14 245th of 283 higher than 35 of 283 other Healthy Volunteers trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT01046513, the US trial registry maintained by the National Library of Medicine. NCT01046513 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.